Skip to main content

Table 2 Number of reports and reporting odds ratio of BRONJ stratified by formulations and dosages

From: Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events

Dosage form Drug name Case Non-case Total Reporting odds ratio (95 % CI)
Intravenous Pamidronate   223 171 394 315.0 (256.3 − 387.0)
   30 mg − 45 mga 44 59 103 159.4 (107.5 − 236.2)
   90 mga 66 48 114 298.0 (204.8 − 433.6)
  Zoledronate   809 972 1,781 346.2 (308.2 − 388.8)
   4 mga 494 651 1,145 226.6 (198.8 − 258.3)
Oral Arendronate (oral)   414 1,252 1,666 92.3 (81.4 − 104.5)
   5 mga 155 388 543 91.7 (75.6 − 111.3)
   35 mga 202 702 904 68.2 (57.8 − 80.4)
  Risedronate   152 721 873 48.4 (40.3 − 58.0)
   2.5 mga 73 374 447 42.5 (32.9 − 54.8)
   17.5 mga 35 213 248 34.9 (24.3 − 50.1)
  1. aReports completed with dosage amount were analyzed